Impact of Omicron on sick leave across industries: A population-wide study

Grøsland, Mari; Reme, Bjørn‐Atle; Gjefsen, Hege Marie

doi:10.1177/14034948221123163

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We posit that these differences could be attributed to job adaptability to work-from-home and self-pacing, i.e., persons with a post-graduate education may work desk jobs whereas persons with a higher education of 2-4 years (e.g., nurse, preschool teacher, bachelor of engineering) may need to be on-site. Similar findings were reported in a Norwegian study, which estimated the industry-specific impact of the Omicron wave on sick leave compared to corresponding months from 2017-2020 (37). Persons within the food and accommodation industry had the highest increase in sick leave (4.4 percentage points increase, 95% CI 4.3-4.5), suggesting that individuals with jobs not-suited for work from home required more sick leave.…”

Section: Industrysupporting

confidence: 83%

Covid-19 and post-acute sick leave: a hybrid register and questionnaire study in the adult Danish population

O'Regan

Svalgaard

Sørensen

et al. 2023

Preprint

View full text Add to dashboard Cite

Long covid follows 10-20% of first-time SARS-CoV-2 infections, but the societal burden of long covid and risk factors for the condition are not well-understood. Here, we report findings about self-reported sick leave and risk factors thereof from a hybrid survey and register study, which included 37,482 RT-PCR confirmed SARS-CoV-2 cases and 51,336 test-negative controls who were tested during the index and alpha waves. An additional 33 individuals per 1000 took substantial sick leave following acute infection compared to persons with no known history of infection, where substantial sick leave was defined as >1 month of sick leave within the period 1-9 months after the RT-PCR test date. Being female, ≥50 years, and having certain pre-existing conditions such as fibromyalgia increased risks for taking substantial sick leave. Further research exploring this heterogeneity is urgently needed and may provide important evidence for more targeted preventative strategies.

show abstract

Section: Industrysupporting

confidence: 83%

Covid-19 and post-acute sick leave: a hybrid register and questionnaire study in the adult Danish population

O'Regan

Svalgaard

Sørensen

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…1 Patients infected with the Omicron variant generally experience mild symptoms [2][3][4] but may have more absences from work. 5 Despite the global administration of vaccinations, there has been emergence of Omicron BA.5*, XBB*, and BQ.1* sublineages, which can evade host immunity. 6,7 Several antiviral drugs against SARS-CoV-2 infection are available worldwide, such as remdesivir, 8 molnupiravir, 9 and ritonavir-boosted nirmatrelvir.…”

Section: Introductionmentioning

confidence: 99%

“…COVID-19 rapidly spread worldwide, and in November 2021, the SARS-CoV-2 Omicron variant was declared a variant of concern . Patients infected with the Omicron variant generally experience mild symptoms but may have more absences from work . Despite the global administration of vaccinations, there has been emergence of Omicron BA.5*, XBB*, and BQ.1* sublineages, which can evade host immunity …”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19

Yotsuyanagi,

Ohmagari,

Doi

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceTreatment options for COVID-19 are warranted irrespective of the presence of risk factors for severe disease.ObjectiveTo assess the efficacy and safety of ensitrelvir in patients with mild to moderate COVID-19.Design, Setting, and ParticipantsThis phase 3 part of a phase 2/3, double-blind, placebo-controlled randomized clinical trial was conducted from February 10 to July 10, 2022, with a 28-day follow-up period, at 92 institutions in Japan, Vietnam, and South Korea. Patients (aged 12 to &lt;70 years) with mild to moderate COVID-19 within 120 hours of positive viral test results were studied.InterventionsPatients were randomized (1:1:1) to receive 125 mg of once-daily ensitrelvir (375 mg on day 1), 250 mg of once-daily ensitrelvir (750 mg on day 1), or placebo for 5 days.Main Outcomes and MeasuresThe primary end point was the time to resolution of the composite of 5 characteristic symptoms of SARS-CoV-2 Omicron infection, assessed using a Peto-Prentice generalized Wilcoxon test stratified by vaccination history. Virologic efficacy and safety were also assessed.ResultsA total of 1821 patients were randomized, of whom 1030 (347 in the 125-mg ensitrelvir group, 340 in the 250-mg ensitrelvir group, and 343 in the placebo group) were randomized in less than 72 hours of disease onset (primary analysis population). The mean (SD) age in this population was 35.2 (12.3) years, and 552 (53.6%) were men. A significant difference was observed between the 125-mg ensitrelvir group and the placebo group (P = .04 with a Peto-Prentice generalized Wilcoxon test). The difference in median time was approximately 1 day between the 125-mg ensitrelvir group and the placebo group (167.9 vs 192.2 hours; difference, −24.3 hours; 95% CI, −78.7 to 11.7 hours). Adverse events were observed in 267 of 604 patients (44.2%) in the 125-mg ensitrelvir group, 321 of 599 patients (53.6%) in the 250-mg ensitrelvir group, and 150 of 605 patients (24.8%) in the placebo group, which included a decrease in high-density lipoprotein level (188 [31.1%] in the 125-mg ensitrelvir group, 231 [38.6%] in the 250-mg ensitrelvir group, and 23 [3.8%] in the placebo group). No treatment-related serious adverse events were reported.Conclusions and RelevanceIn this randomized clinical trial, 125-mg ensitrelvir treatment reduced the time to resolution of the 5 typical COVID-19 symptoms compared with placebo in patients treated in less than 72 hours of disease onset; the absolute difference in median time to resolution was approximately 1 day. Ensitrelvir demonstrated clinical and antiviral efficacy without new safety concerns. Generalizability to populations outside Asia should be confirmed.Trial RegistrationJapan Registry of Clinical Trials Identifier: jRCT2031210350

show abstract

A hybrid register and questionnaire study of Covid-19 and post-acute sick leave in Denmark

O’Regan,

Svalgaard,

Sørensen

et al. 2023

Nat Commun

View full text Add to dashboard Cite

Post-acute sick leave is an underexplored indicator of the societal burden of SARS-CoV-2. Here, we report findings about self-reported sick leave and risk factors thereof from a hybrid survey and register study, which include 37,482 RT-PCR confirmed SARS-CoV-2 cases and 51,336 test-negative controls who were tested during the index- and alpha-dominant waves. We observe that an additional 33 individuals per 1000 took substantial sick leave following acute infection compared to persons with no known history of infection, where substantial sick leave is defined as >1 month of sick leave within the period 1–9 months after the RT-PCR test date. Being female, 50–65 years, or having certain pre-existing health conditions such as obesity, chronic lung diseases, and fibromyalgia each increase risk for taking substantial sick leave. Altogether, these results may help motivate improved diagnostic and treatment options for persons living with post-Covid conditions.

show abstract

Impact of Omicron on sick leave across industries: A population-wide study

Cited by 3 publications

References 7 publications

Covid-19 and post-acute sick leave: a hybrid register and questionnaire study in the adult Danish population

Covid-19 and post-acute sick leave: a hybrid register and questionnaire study in the adult Danish population

Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19

A hybrid register and questionnaire study of Covid-19 and post-acute sick leave in Denmark

Contact Info

Product

Resources

About